(18)F-FDG and (68)Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study

S. Taralli, M. Sollini, M. Milella, G. Perotti, A. Filice, M. Menga, A. Versari, V. Rufini

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin tumor. Currently, (18)F-fluoro-deoxy-glucose ((18)F-FDG) PET/CT is the functional imaging modality of choice. Few data are available on the use of (68)Ga-somatostatin analogs. The aim of our study was to evaluate and compare the diagnostic performance of (18)F-FDG and (68)Ga-somatostatin analog PET/CT in MCC patients. RESULTS: Fifteen patients (12 males, 3 females; median age 73 years; range 41-81 years) with histologically proven MCC (4 with unknown primary lesion) who underwent both (18)F-FDG and (68)Ga-somatostatin analog PET/CT for staging, re-staging, or treatment response assessment were retrospectively evaluated. Results of both studies were qualitatively analyzed and compared on a patient- and lesion-based analysis, using histology or clinical/radiological follow-up as reference standard for final diagnosis. According to final diagnosis, 8/15 patients had at least one MCC lesion and 7/15 had no evidence of disease. On a patient-based analysis, (18)F-FDG and (68)Ga-somatostatin analogs correctly classified as positive 8/8 (100% sensitivity) patients and as negative 6/7 (85.7% specificity) and 5/7 (71.4% specificity) patients, respectively, with no significant difference. On a lesion-based analysis, (18)F-FDG detected 67/75 lesions (89%) and (68)Ga-somatostatin analogs 69/75 (92%), with no significant difference. In four patients with unknown primary MCC, both tracers failed to identify the primary MCC site. CONCLUSIONS: Our preliminary data suggest that (18)F-FDG and (68)Ga-somatostatin analog PET/CT provide good and equivalent diagnostic performance, adding interesting insights into the complex MCC biology. However, these results do not suggest that (18)F-FDG PET/CT should be replaced by (68)Ga-somatostatin receptor imaging, which should be performed in addition, according to clinical indication, to the perspective of "personalized medicine."
Original languageEnglish
Pages (from-to)64
JournalEJNMMI Research
Volume8
Issue number1
DOIs
Publication statusPublished - Jul 21 2018

Fingerprint

Merkel Cell Carcinoma
Somatostatin
Somatostatin Receptors
Precision Medicine
Neuroendocrine Tumors
Cell Biology
Histology
Glucose
Skin

Keywords

  • 18F-FDG
  • 68Ga-somatostatin analogs
  • Merkel cell carcinoma
  • Positron emission tomography/computed tomography

Cite this

(18)F-FDG and (68)Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study. / Taralli, S.; Sollini, M.; Milella, M.; Perotti, G.; Filice, A.; Menga, M.; Versari, A.; Rufini, V.

In: EJNMMI Research, Vol. 8, No. 1, 21.07.2018, p. 64.

Research output: Contribution to journalArticle

Taralli, S. ; Sollini, M. ; Milella, M. ; Perotti, G. ; Filice, A. ; Menga, M. ; Versari, A. ; Rufini, V. / (18)F-FDG and (68)Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study. In: EJNMMI Research. 2018 ; Vol. 8, No. 1. pp. 64.
@article{f7329c02fd3b478fa2733d2e2b10f07f,
title = "(18)F-FDG and (68)Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study",
abstract = "BACKGROUND: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin tumor. Currently, (18)F-fluoro-deoxy-glucose ((18)F-FDG) PET/CT is the functional imaging modality of choice. Few data are available on the use of (68)Ga-somatostatin analogs. The aim of our study was to evaluate and compare the diagnostic performance of (18)F-FDG and (68)Ga-somatostatin analog PET/CT in MCC patients. RESULTS: Fifteen patients (12 males, 3 females; median age 73 years; range 41-81 years) with histologically proven MCC (4 with unknown primary lesion) who underwent both (18)F-FDG and (68)Ga-somatostatin analog PET/CT for staging, re-staging, or treatment response assessment were retrospectively evaluated. Results of both studies were qualitatively analyzed and compared on a patient- and lesion-based analysis, using histology or clinical/radiological follow-up as reference standard for final diagnosis. According to final diagnosis, 8/15 patients had at least one MCC lesion and 7/15 had no evidence of disease. On a patient-based analysis, (18)F-FDG and (68)Ga-somatostatin analogs correctly classified as positive 8/8 (100{\%} sensitivity) patients and as negative 6/7 (85.7{\%} specificity) and 5/7 (71.4{\%} specificity) patients, respectively, with no significant difference. On a lesion-based analysis, (18)F-FDG detected 67/75 lesions (89{\%}) and (68)Ga-somatostatin analogs 69/75 (92{\%}), with no significant difference. In four patients with unknown primary MCC, both tracers failed to identify the primary MCC site. CONCLUSIONS: Our preliminary data suggest that (18)F-FDG and (68)Ga-somatostatin analog PET/CT provide good and equivalent diagnostic performance, adding interesting insights into the complex MCC biology. However, these results do not suggest that (18)F-FDG PET/CT should be replaced by (68)Ga-somatostatin receptor imaging, which should be performed in addition, according to clinical indication, to the perspective of {"}personalized medicine.{"}",
keywords = "18F-FDG, 68Ga-somatostatin analogs, Merkel cell carcinoma, Positron emission tomography/computed tomography",
author = "S. Taralli and M. Sollini and M. Milella and G. Perotti and A. Filice and M. Menga and A. Versari and V. Rufini",
note = "LR: 20180809; JID: 101560946; OTO: NOTNLM; 2018/06/06 00:00 [received]; 2018/07/06 00:00 [accepted]; 2018/07/23 06:00 [entrez]; 2018/07/23 06:00 [pubmed]; 2018/07/23 06:01 [medline]; epublish",
year = "2018",
month = "7",
day = "21",
doi = "10.1186/s13550-018-0423-3 [doi]",
language = "English",
volume = "8",
pages = "64",
journal = "EJNMMI Research",
issn = "2191-219X",
publisher = "Springer Berlin",
number = "1",

}

TY - JOUR

T1 - (18)F-FDG and (68)Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study

AU - Taralli, S.

AU - Sollini, M.

AU - Milella, M.

AU - Perotti, G.

AU - Filice, A.

AU - Menga, M.

AU - Versari, A.

AU - Rufini, V.

N1 - LR: 20180809; JID: 101560946; OTO: NOTNLM; 2018/06/06 00:00 [received]; 2018/07/06 00:00 [accepted]; 2018/07/23 06:00 [entrez]; 2018/07/23 06:00 [pubmed]; 2018/07/23 06:01 [medline]; epublish

PY - 2018/7/21

Y1 - 2018/7/21

N2 - BACKGROUND: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin tumor. Currently, (18)F-fluoro-deoxy-glucose ((18)F-FDG) PET/CT is the functional imaging modality of choice. Few data are available on the use of (68)Ga-somatostatin analogs. The aim of our study was to evaluate and compare the diagnostic performance of (18)F-FDG and (68)Ga-somatostatin analog PET/CT in MCC patients. RESULTS: Fifteen patients (12 males, 3 females; median age 73 years; range 41-81 years) with histologically proven MCC (4 with unknown primary lesion) who underwent both (18)F-FDG and (68)Ga-somatostatin analog PET/CT for staging, re-staging, or treatment response assessment were retrospectively evaluated. Results of both studies were qualitatively analyzed and compared on a patient- and lesion-based analysis, using histology or clinical/radiological follow-up as reference standard for final diagnosis. According to final diagnosis, 8/15 patients had at least one MCC lesion and 7/15 had no evidence of disease. On a patient-based analysis, (18)F-FDG and (68)Ga-somatostatin analogs correctly classified as positive 8/8 (100% sensitivity) patients and as negative 6/7 (85.7% specificity) and 5/7 (71.4% specificity) patients, respectively, with no significant difference. On a lesion-based analysis, (18)F-FDG detected 67/75 lesions (89%) and (68)Ga-somatostatin analogs 69/75 (92%), with no significant difference. In four patients with unknown primary MCC, both tracers failed to identify the primary MCC site. CONCLUSIONS: Our preliminary data suggest that (18)F-FDG and (68)Ga-somatostatin analog PET/CT provide good and equivalent diagnostic performance, adding interesting insights into the complex MCC biology. However, these results do not suggest that (18)F-FDG PET/CT should be replaced by (68)Ga-somatostatin receptor imaging, which should be performed in addition, according to clinical indication, to the perspective of "personalized medicine."

AB - BACKGROUND: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin tumor. Currently, (18)F-fluoro-deoxy-glucose ((18)F-FDG) PET/CT is the functional imaging modality of choice. Few data are available on the use of (68)Ga-somatostatin analogs. The aim of our study was to evaluate and compare the diagnostic performance of (18)F-FDG and (68)Ga-somatostatin analog PET/CT in MCC patients. RESULTS: Fifteen patients (12 males, 3 females; median age 73 years; range 41-81 years) with histologically proven MCC (4 with unknown primary lesion) who underwent both (18)F-FDG and (68)Ga-somatostatin analog PET/CT for staging, re-staging, or treatment response assessment were retrospectively evaluated. Results of both studies were qualitatively analyzed and compared on a patient- and lesion-based analysis, using histology or clinical/radiological follow-up as reference standard for final diagnosis. According to final diagnosis, 8/15 patients had at least one MCC lesion and 7/15 had no evidence of disease. On a patient-based analysis, (18)F-FDG and (68)Ga-somatostatin analogs correctly classified as positive 8/8 (100% sensitivity) patients and as negative 6/7 (85.7% specificity) and 5/7 (71.4% specificity) patients, respectively, with no significant difference. On a lesion-based analysis, (18)F-FDG detected 67/75 lesions (89%) and (68)Ga-somatostatin analogs 69/75 (92%), with no significant difference. In four patients with unknown primary MCC, both tracers failed to identify the primary MCC site. CONCLUSIONS: Our preliminary data suggest that (18)F-FDG and (68)Ga-somatostatin analog PET/CT provide good and equivalent diagnostic performance, adding interesting insights into the complex MCC biology. However, these results do not suggest that (18)F-FDG PET/CT should be replaced by (68)Ga-somatostatin receptor imaging, which should be performed in addition, according to clinical indication, to the perspective of "personalized medicine."

KW - 18F-FDG

KW - 68Ga-somatostatin analogs

KW - Merkel cell carcinoma

KW - Positron emission tomography/computed tomography

U2 - 10.1186/s13550-018-0423-3 [doi]

DO - 10.1186/s13550-018-0423-3 [doi]

M3 - Article

VL - 8

SP - 64

JO - EJNMMI Research

JF - EJNMMI Research

SN - 2191-219X

IS - 1

ER -